Health1 min read

Govt mulls tight scrutiny of antimicrobial drugs

By · Published by Everything Blog

In short

Under the proposed notification from the Ministry of Health and Family Welfare, antimicrobials will be brought under the formal regulatory definition of a "new drug." Pharmaceutical manufacturers must obtain permission from the Central Licensing Authority prior to applying for state-level production licences. The policy responds directly to worries that permits were previously issued without vital checks, including bioequivalence assessments and stability testing. Existing licence holders will not be impacted, as current operations remain valid without requiring fresh approvals.

Key points

  • The proposed regulatory amendment classifies antimicrobials under the formal definition o…: The proposed regulatory amendment classifies antimicrobials under the formal definition of a new drug to strengthen oversight.
  • The new scrutiny requirements will apply prospectively without requiring existing licence…: The new scrutiny requirements will apply prospectively without requiring existing licence holders to request fresh operational approvals.
  • Enhanced regulatory oversight is specifically designed to address antimicrobial resistanc…: Enhanced regulatory oversight is specifically designed to address antimicrobial resistance by guaranteeing product quality, safety, and efficacy.

Sources checked by our analysis pipeline: 1

The proposed amendment to the New Drugs and Clinical Trials Rules, 2019, will require manufacturers to obtain permission from the Central Licensing Authority (CLA) before approaching state licensing authorities for manufacturing licences for antimicrobial products.

"The requirement will apply prospectively, with the government clarifying that existing manufacturing licences will remain valid and current licence holders will not have to seek fresh approvals," an official said.

The health and family welfare minitry has proposed the amendment through a draft notification seeking to include 'antimicrobials' in the definition of a 'new drug' under Rule 2(1)(w)(v) of the New Drugs and Clinical Trials Rules, 2019.

The ministry said the proposal was intended to serve as an additional regulatory safeguard against AMR by strengthening oversight of antimicrobial products and ensuring appropriate scrutiny of their quality, safety and efficacy before new manufacturing licences are granted.

The amendment had been proposed in view of concerns regarding the grant of manufacturing licences for antimicrobial products without adequate regulatory scrutiny, including assessments such as bioavailability/bioequivalence and stability studies, the ministry said.

(Catch all the Business News, Breaking News…

Health